A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
Conditions
Hemophilia A
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
UC Davis Cancer Center, Sacramento, California, United States
Georgetown Uni Medical Center, Washington D.C., District of Columbia, United States
Indiana Hemophilia & Thrombosis center, Indianapolis, Indiana, United States
University of Iowa Hospitals and Clnics Dept of Pediatrics, Iowa City, Iowa, United States
British Columbia Children's Hospital, Vancouver, British Columbia, Canada
Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada
IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardy, Italy
Istituto Clinico Humanitas, Rozzano (MI), Lombardy, Italy
Auckland Cancer Trial Centre, Auckland, New Zealand
Uniwersyteckie Centrum Kliniczne, Gda?sk, Poland
Instytut Hematologii i Transfuzjologii, Warsaw, Poland
Hospital Sant Joan de Deu, Esplugues de Llobregat, Barcelona, Spain
Hospital Universitario la Paz, Madrid, Spain
Hospital Regional Universitario Carlos Haya, Málaga, Spain
Study leads
Clinical Trials
Study Director
Hoffmann-La Roche